Ascites Market Research Report- Global Forecast till 2023
ID: MRFR/HC/1377-CRR | January, 2018 | Region: Global | 85 pages | Cooked Research Reports
Global Ascites Market Research Report: By Type (Transudative, Exudate Ascites), Diagnosis (Ultrasound, CT Scan, Laparoscopy, Angiography), Treatment (Surgeries, others), End Users (Ambulatory Surgical Centers, Hospitals, Clinics) – Forecast till 2023
Market Scenario
Ascites is an abnormal accumulation of fluid in the abdominal cavity. Liver cirrhosis is the most common case of ascites. Its presence is a sign of significant portal hypertension. Other less common factors that may contribute to ascites development are heart failure, kidney failure, cancers, and infection in the pancreas. Malignant ascites has a characteristic role in the progression of ovarian cancer. Malignancy-related ascites have also been observed in malignancies of breast, lung, pancreas, gastric, and liver. Ascites can be detected by physical examination at a volume greater than 1.5 ascites. For a smaller amount of fluid, ultrasound and CT scan are preferred.
Notably, rising prevalence of cirrhosis is the key factors driving the ascites market. As per the study published in Hepatology journal in 2016, it is found that prevalence of the chronic liver disease is higher among Japanese Americans i.e. 6.9%. It is also stated that in whites, alcoholic liver disease was observed as the most common cause of cirrhosis i.e. 38.2%, whereas hepatitis C virus was most common in African Americans i.e. 29.8%
Improvement in reimbursement policies and increasing occurrence of cancer across the globe are also fuelling the market growth. According to a study published in the Cancer Biology & Medicine journal in 2017, it is found that ovarian cancer is the seventh most frequently diagnosed cancer among women in the world with an estimation of 239,000 new cases, and 152,000 deaths worldwide annually.
However, complications associated with ascites treatment may hinder the growth of the market over the forecast period. According to a study published in the Canadian Journal of Gastroenterology and Hepatology in 2016, serial large volume paracentesis (LVP) is considered as the first-line treatment for refractory ascites, and is also performed in an outpatient every 2 weeks. But there are certain complications associated with LVP such as bleeding, catheter fragmentation into the abdominal wall, and small bowel perforation.
The global ascites market is expected to grow at a CAGR of 4.0% during the forecast period 2017-2023.
Intended Audience
- Medical Devices Companies
- Hospitals & Clinics
- Diagnostic Centers
- Research and Development (R&D) Companies
- Government Research Institute
- Academic Institutes and Universities
Figure: Global Ascites Market by Type Market Share, 2016 (%)
Sources: Annual reports, Press release, White paper, Company presentation
Segmentation
The global ascites market is segmented on the basis of type, diagnosis, treatment, and end user.
On the basis of the type, the market is classified into transudative ascites, and exudate ascites.
On the basis of the diagnosis, the market is segmented into ultrasound, CT scan, laparoscopy, angiography, and others.
On the basis of the treatment, the market is segmented into surgeries and others. The surgeries segment is further sub-segmented into peritoneovenous shunting, liver transplantation, transjugular intrahepatic portosystemic shunt (TIPS), and other surgeries.
On the basis of the end -users, the market is segmented into hospital, and clinics, ambulatory surgical centers, diagnostic centers, and others.
Key Findings
- The global ascites market is expected to reach USD 3710.4 million by 2023 at a CAGR of 4.0%.
- On the basis of the diagnosis, the ultrasound segment is expected to command the largest market share of 9% over the review period and it is also expected to grow at the fastest CAGR of 4.4% during the forecast period 2017-2023
- On the basis of the type, exudate ascites is expected to command the largest market share of 55.8% over the review period and it is also expected to grow at the fastest CAGR of 4.4% during the forecast period 2017-2023
- The Americas hold the largest share of the global ascites market and is expected to reach USD 1,292.2 million by 2023
- Asia Pacific is the fastest growing market, which is expected to grow at a CAGR of 4.5% over the 2017-2023
Regional Analysis
The Americas dominate the ascites market owing to the well-developed technology, high healthcare expenditure, rising prevalence of cirrhosis, and the presence of the leading players in the region. According to the data suggested by the Centers for Disease Control and Prevention in 2015, around 1.6 % adults have been diagnosed with the chronic liver disease in the United States i.e. 3.9 million. It is also stated that from 2000 to 2015 death rates due to the chronic liver disease and cirrhosis was increased by 31% in the United States among individuals aged 45–64 years.
Europe holds the second position in the ascites market. It is expected that the support provided by the government bodies for research & development and increasing number of surgeries drives the market in this region. Liver is also very prevalent in European region. Owing to the increasing alcohol consumption and obesity, liver cirrhosis is the third most common cause of premature mortality in the UK as compared to other countries in Western Europe, suggested by a study published in BMJ Open in 2017
Asia Pacific region is projected to be the fastest growing region during the forecast period. Rapidly improving technology and the presence of huge patient pool drive the growth of this market in Asia Pacific region.
The Middle East and Africa hold the least share of the ascites market owing to the presence of poor and slow developing countries, especially, in African region.
Key Players
Some of key the players in the ascites market are Sequana Medical, BioVie, PharmaCyte Biotech Inc., Fresenius SE & Co. KGaA, BD, GI Supply, Medtronic plc, and others.
Research Methodology
Sources: Annual reports, Press release, White paper, and Company presentation
